Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer 机翻标题: 暂无翻译,请尝试点击翻译按钮。

来源
Gynecologic Oncology: An International Journal
年/卷/期
2018 / 150 / 3
页码
446-450
ISSN号
0090-8258
作者单位
Department of Research, Netherlands Comprehensive Cancer Organization (IKNL);Department of Research, Netherlands Comprehensive Cancer Organization (IKNL);GROW - School for Oncology and Developmental Biology;Department of Medical Oncology, University Medical Centre Utrecht;Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG);Department of Obstetrics and Gynecology, Maastricht University Medical Centre;Department of Medical Oncology, The Netherlands Cancer Institute;
作者
M. Timmermans;M.A. van der Aa;R.I. Lalisang;P.O. Witteveen;K.K. Van de Vijver;R.F. Kruitwagen;G.S. Sonke;
摘要
ObjectiveTreatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to adjuvant chemotherapy (TTC) was associated with clinical outcome. MethodsWe identified all Dutch patients who received optimal or complete debulking surgery for primary EOC (FIGO IIb-IV) between 2008 and 2015 from the Netherlands Cancer Registry. TTC was divided into three groups based on the interquartile range (IQR). Early ( 75%) TTC were compared to intermediate TTC (25–75%). Logistic regression was used to identify factors associated with a prolonged TTC and multivariable Cox regression to evaluate the independent effect of treatment interval on overall survival (OS). Patients receiving primary debulking surgery (PDS) and patients receiving interval debulking surgery (IDS) were analyzed separately. Results4097 patients were included, 1612 underwent PDS and 2485 IDS. Median TTC was 29?days (IQR 24–37). Age?≥?65, complete debulking surgery, postoperative complications, and hospitalization ≥10?days were independently associated with a longer TTC for both PDS and IDS. TTC in the longest quartile was associated with poor OS after both PDS (Hazard Rate (HR) 1.43, 95% CI 1.09–1.88) and NACT-IDS (HR 1.22 (1.02–1.47)) when compared to the intermediate TTC, but only in patients with no macroscopic residual disease after surgery. ConclusionsOur study provides evidence that delayed initiation of adjuvant chemotherapy is an independent prognostic factor for worse overall survival after complete (interval)debulking surgery. We advise to start adjuvant chemotherapy within five to six weeks after debulking surgery.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
关键词/主题词
Epithelial ovarian cancer;Primary debulking surgery;Neoadjuvant chemotherapy;Adjuvant chemotherapy;Timing;Overall survival;
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部